IFIH1 and clinically amyopathic dermatomyositis: For patients with refractory anti‐MDA5 antibody‐positive CADM and rapidly progressive interstitial pneumonia who are positive for anti‐MDA5 antibodies, tacrolimus trough concentration‐escalating dual therapy (glucocorticoids combined with tacrolimus) is a therapeutic strategy worth considering.